Neervannan Seshadri 4

What Happened

• Neervannan Seshadri, Chief Operating Officer of Tarsus Pharmaceuticals (TARS), had 26,287 restricted stock units (RSUs settle/convert) vest on March 15, 2026. The company issued 26,287 shares pursuant to settlement of vested RSUs (reported as an acquisition), and an equal total of 26,287 shares were recorded as dispositions at $0.00 to satisfy tax withholding. No cash proceeds were reported and the transaction appears to be a routine vest-and-withhold event rather than an open-market buy or sell.

Key Details

• Transaction date: March 15, 2026; Form 4 filed March 17, 2026 (timely filing).
• Gross shares issued: 26,287 (RSU settlement). Shares withheld/disposed for taxes: 5,097 + 8,148 + 8,020 + 5,022 = 26,287.
• Reported prices: issuance N/A for RSU settlement; withholding/disposals recorded at $0.00 (no cash sale proceeds).
• Footnotes: F1 confirms shares issued upon settlement of vested RSUs. F3–F7 describe the RSU grants and vesting schedules (grants from 2022–2025 with 25% vesting each March 15 of the applicable years). F2 discloses a household holding (the Reporting Person’s daughter) and disclaims beneficial ownership of those shares.
• Shares owned after the transaction are not specified in the provided excerpt.

Context

• This was a scheduled RSU vesting and tax-withholding event (not a market sale). The Form shows conversion/settlement of RSUs (derivative code M) and immediate withholding of an equivalent number of shares for taxes—common for RSU settlements and not necessarily reflective of insider sentiment.